Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00928434 · ClinicalTrials.gov registry record · Phase 3
A Study of Degarelix in Patients With Prostate Cancer
A Phase 3 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 409
- Enrollment target
NCT00928434 is a Phase 3 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 409 participants.
The verdict
NCT00928434, a Phase 3 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 409 participants
- Enrollment target
Study Summary
The purpose of this study was to see if giving Degarelix every month for 7 months then stop treatment for 7 months (intermittent therapy) would show a reduction of negative effects of androgen deprivation therapy by increasing the quality of life while keeping prostate specific antigen (PSA) levels suppressed.
Interventions
- DRUG Degarelix
- DRUG Leuprolide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 409 participants |
| Start Date | 2009-05 |
| Est. Completion | 2012-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00928434
The ClinicalTrials.gov registry entry for NCT00928434 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 409 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Degarelix is the first listed.
NCT00928434 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00928434 about?
NCT00928434 is a clinical study titled "A Study of Degarelix in Patients With Prostate Cancer". The purpose of this study was to see if giving Degarelix every month for 7 months then stop treatment for 7 months (intermittent therapy) would show a reduction of negative effects of androgen deprivation therapy by increasing the quality of life while keeping prostate specific antigen (PSA) levels ...
What is the current status of trial NCT00928434?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 409 participants. The study started on 2009-05. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00928434?
The interventions under investigation include: Degarelix (DRUG), Leuprolide (DRUG).
Who is sponsoring clinical trial NCT00928434?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.